検索結果 - Ulrich Lücking

  • 検索結果 1 - 4 結果 / 4
結果の絞り込み
  1. 1
    BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

    BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application 著者: Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau, Wolfram Steinke, Christoph A. Schatz, Dominik Mumberg, Karl Ziegelbauer

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9

    Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9 著者: Pelin Ayaz, Dorothee Andres, Dennis Kwiatkowski, Carl‐Christian Kolbe, Philip Lienau, Gerhard Siemeister, Ulrich Lücking, Christian M. Stegmann

    出版事項 2016
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

    The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models 著者: Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer, Sven Golfier, Christoph A. Schatz, Simon J. Baumgart, Bernard Haendler, Pascale Lejeune, Andreas Schlicker, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg

    出版事項 2019
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

    Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer 著者: Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Karsten Denner, Ulf Bömer, Martina Schäfer, Knut Eis, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Bert Klebl, Axel Choidas, Peter Nußbaumer, Matthias Baumann, Carsten Schultz‐Fademrecht, Gerd Rühter, Jan Eickhoff, Michael Brands

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: